Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
10:08am, Monday, 08'th Jun 2026
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
10:06am, Monday, 08'th Jun 2026
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.
Nurix Therapeutics Stock Pops on Roche Partnership
09:45am, Monday, 08'th Jun 2026
Nurix Therapeutics Inc (NASDAQ:NRIX) stock is up 15.7% to trade at $16.94, after the biotech company announced a collaboration and licensing agreement with Roche for blood cancer treatment bexobrutid
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
09:26am, Monday, 08'th Jun 2026
Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday's premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
03:51am, Monday, 08'th Jun 2026
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
01:47am, Monday, 08'th Jun 2026
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
07:31pm, Friday, 05'th Jun 2026
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose
Zealand touts promising tolerability data for obesity drug in mid-stage study
04:47pm, Friday, 05'th Jun 2026
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering its push to take on market lead
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
01:05pm, Friday, 05'th Jun 2026
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
11:33am, Thursday, 04'th Jun 2026
New Roche test targeting detection of Bundibugyo virus supports efforts to address critical need during ongoing outbreaks 1 Roche's unique outbreak response capabilities enabled rapid development of t
Roche chairman likens US tariff policy to 'blackmail'
10:53am, Thursday, 04'th Jun 2026
The chairman of Swiss pharmaceutical giant Roche hit out at U.S. tariff policies on Thursday, likening them to "blackmail", and said protectionism by the United States and China was the firm's b
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
06:00am, Wednesday, 03'rd Jun 2026
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RA
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
05:12pm, Tuesday, 02'nd Jun 2026
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
